What's the difference between araroba and chrysarobin?
Araroba
Definition:
Example Sentences:
Chrysarobin
Definition:
(n.) A bitter, yellow substance forming the essential constituent of Goa powder, and yielding chrysophanic acid proper; hence formerly called also chrysphanic acid.
Example Sentences:
(1) Following a single application of 220 nmol chrysarobin, ODC activity began to rise at 24 h reaching a peak at 56 h and returned to normal after 96 h. When 5 separate applications of 220 nmol chrysarobin were applied in multiple application protocols, an alteration in the ODC induction response was observed.
(2) He intended to substitute Chrysarobin, a synthetic product, which causes strong discolouring and irritation of skin.
(3) Scatchard analyses revealed that the inhibition by chrysarobin was due to a decrease in the number of both high- and low-affinity classes of EGF receptors.
(4) Interestingly, chrysarobin was approximately twice as active as a skin tumor promoter when applied once weekly versus twice weekly.
(5) Other non-TPA type tumor promoters, i.e., chrysarobin, 7-bromomethylbenz[a]anthracene, benzoylperoxide, okadaic acid and palytoxin, did not potentiate the TPA-caused PGE2 release.
(6) Naturally-occurring agonists at this receptor may include members of the cathartic class of drugs such as colocynth, chrysarobin, etc.
(7) The present study was designed to compare the skin tumor promoting and epidermal ornithine decarboxylase (ODC) inducing activities of various structural analogs of anthralin (1,8-dihydroxy-9-anthrone) and chrysarobin (1,8-dihydroxy-3-methyl-9-anthrone).
(8) Although dose-response comparisons indicated that chrysarobin was several orders of magnitude less potent than TPA for promoting papilloma formation, this anthrone was 1.5 to 2 times more potent than anthralin.
(9) In this regard, putrescine levels were elevated at 6 and 24 h after a single application of chrysarobin.
(10) In addition, chrysarobin treatment following 10 wk of TPA promotion did not enhance the progression of preexisting papillomas to carcinomas.
(11) However, induction was suppressed by chrysarobin, an anthralin analog that causes PKC down-regulation in the absence of prior activation.
(12) However, the number of papillomas per mouse that were greater than or equal to 4 mm in diameter was significantly reduced in both chrysarobin- and TPA-treated mice.
(13) Maximal papilloma responses were achieved by 15 weeks of promotion with TPA whereas at least 25 weeks of promotion were necessary to achieve maximal papilloma responses with chrysarobin or anthralin indicating marked differences in tumor latency between the two classes of compounds.
(14) Chrysarobin was also a much more effective skin tumor promoter when the start of promotion was delayed by an additional 10 weeks.
(15) Acid washing restored EGF binding to control levels in membrane preparations obtained 24 h after a single application, whereas acid washing of membrane preparations obtained 24 h after a second application of TPA or chrysarobin increased binding (2.5-fold and 1.5-fold that of the control, respectively).
(16) In addition, copper(II)bis(diisopropylsalicylate) was found to inhibit both ODC induction and skin tumor promotion by chrysarobin.
(17) Inhibition of epidermal DNA synthesis following treatment with chrysarobin was observed within a few hours after treatment and remained depressed until approximately 36 h after treatment.
(18) The mechanism by which chrysarobin inhibited the binding of EGF to its receptor involved neither direct activation nor membrane translocation of epidermal protein kinase C, whereas the rapid decrease in EGF binding induced by TPA was consistent with its ability to activate protein kinase C. Structure-activity relationships for EGF binding inhibition by anthrones revealed that inhibition was inversely proportional to chain length at the C10-position, which correlated closely with oxidation rate and skin tumor-promoting activity.
(19) In addition, putrescine levels were elevated with a second major peak at 64 h after chrysarobin which coincided with elevated epidermal ornithine decarboxylase activity.
(20) This article reviews the history of selected therapeutic agents for psoriasis: arsenic (including Fowler's solution), ammoniated mercury, chrysarobin and anthralin, tars, aminopterin and methotrexate, and corticosteroids.